Vir Biotechnology Files 8-K on Financials

Ticker: VIR · Form: 8-K · Filed: Feb 26, 2025 · CIK: 1706431

Vir Biotechnology, Inc. 8-K Filing Summary
FieldDetail
CompanyVir Biotechnology, Inc. (VIR)
Form Type8-K
Filed DateFeb 26, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financials, 8-K

Related Tickers: VIR

TL;DR

Vir Bio dropped an 8-K on Feb 26th covering their financials - check it out.

AI Summary

Vir Biotechnology, Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to its business operations.

Why It Matters

This 8-K filing provides investors with crucial updates on Vir Biotechnology's financial performance and operational status.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.

Key Players & Entities

  • Vir Biotechnology, Inc. (company) — Registrant
  • February 26, 2025 (date) — Date of Report

FAQ

What specific financial information is being reported in this 8-K?

The 8-K filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.

What is the exact date of this filing?

The filing was made on February 26, 2025.

What is the principal executive office address for Vir Biotechnology, Inc.?

The address is 1800 Owens Street, Suite 900, San Francisco, California 94158.

What is the SIC code for Vir Biotechnology, Inc.?

The Standard Industrial Classification code is 2836, for Biological Products (No Diagnostic Substances).

What is the Commission File Number for Vir Biotechnology, Inc.?

The Commission File Number is 001-39083.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 26, 2025 regarding Vir Biotechnology, Inc. (VIR).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.